Xbrane Biopharma Ab Stock Cash And Equivalents
| XBRANE Stock | SEK 0.19 0.01 5.00% |
Xbrane Biopharma AB fundamentals help investors to digest information that contributes to Xbrane Biopharma's financial success or failures. It also enables traders to predict the movement of Xbrane Stock. The fundamental analysis module provides a way to measure Xbrane Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xbrane Biopharma stock.
Xbrane |
Xbrane Biopharma AB Company Cash And Equivalents Analysis
Xbrane Biopharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Xbrane Biopharma Cash And Equivalents | 44.32 M |
Most of Xbrane Biopharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xbrane Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Xbrane Biopharma AB has 44.32 M in Cash And Equivalents. This is 94.6% lower than that of the Healthcare sector and 87.68% lower than that of the Drug Manufacturers - Specialty & Generic industry. The cash and equivalents for all Sweden stocks is 98.36% higher than that of the company.
Xbrane Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xbrane Biopharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xbrane Biopharma could also be used in its relative valuation, which is a method of valuing Xbrane Biopharma by comparing valuation metrics of similar companies.Xbrane Biopharma is currently under evaluation in cash and equivalents category among its peers.
Xbrane Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| Gross Profit | (18.27 M) | |||
| EBITDA | (172.74 M) | |||
| Net Income | (188.38 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Current Ratio | 1.45 X | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 | |||
| Market Capitalization | 2.74 B | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
| Z Score | 45.0 | |||
| Net Asset | 688.43 M |
About Xbrane Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.